There was no apparent benefit to continuing oral anticoagulants compared with interruption in patients undergoing transcatheter aortic valve implantation (TAVI), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024. The study is published in the New England Journal of Medicine.
This article was originally published on MedicalXpress.com